<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855035</url>
  </required_header>
  <id_info>
    <org_study_id>Find-AF randomised</org_study_id>
    <nct_id>NCT01855035</nct_id>
  </id_info>
  <brief_title>Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring</brief_title>
  <official_title>A Prospective, Randomised, Controlled Study to Determine the Detection of Atrial Fibrillation by Prolonged and Enhanced Holter Monitoring as Compared to Usual Care in Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether repeated enhanced and prolonged ECG monitoring
      after ischemic stroke results in a higher detection of atrial fibrillation (/flutter)
      compared to usual care (at least 24 hour of cardiac monitoring).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of atrial fibrillation/flutter</measure>
    <time_frame>30 month after study start</time_frame>
    <description>The primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of atrial fibrillation (/flutter) within 12 months after patient's inclusion</measure>
    <time_frame>24 months after study start</time_frame>
    <description>Detection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of atrial fibrillation (/flutter) without hospitalisation</measure>
    <time_frame>30 months after study start</time_frame>
    <description>Detection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of recurrent stroke or systemic embolism</measure>
    <time_frame>24 months after study start</time_frame>
    <description>Recurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total mortality</measure>
    <time_frame>24 months after study start</time_frame>
    <description>Total death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cardiovascular deaths</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cerebrovascular deaths</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of transient ischemic attacks</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of myocardial infarctions</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of bleeding complications</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of atrial fibrillation (/flutter) in extended monitoring period</measure>
    <time_frame>24 months after study start</time_frame>
    <description>Incremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs</measure>
    <time_frame>24 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of correct monitorings</measure>
    <time_frame>24 months after study start</time_frame>
    <description>To assess the feasibility of monitoring procedures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prolonged ECG monitoring</intervention_name>
    <description>10-day Holter ECG measurement</description>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).</description>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting &gt;
             24h consistent with the territory of a major cerebral artery and categorised as
             ischemic) and/or a corresponding lesion on brain imaging.

          -  Stroke symptoms started ≤ 7 days ago.

          -  Age ≥ 60 years.

          -  Modified Rankin scale ≤ 2 (prior to index event).

        Exclusion Criteria:

          -  Known history of atrial fibrillation/flutter or atrial fibrillation/flutter on
             admission ECG.

          -  Indication for oral anticoagulation at randomisation.

          -  Absolute contra-indication against oral anticoagulation at randomisation.

          -  Intracerebral bleeding in medical history.

          -  Patient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.

          -  Significant carotid artery or vertebral artery stenosis &gt; 50% (NASCET classification),
             significant intracranial artery stenosis suspicious of atherosclerotic origin or acute
             arterial dissection explanatory of stroke symptoms.

          -  Implanted pacemaker device or cardioverter/defibrillator.

          -  Life expectancy &lt; 1 year for reasons other than stroke (e.g. metastatic cancer).

          -  Concomitant participation in other controlled randomised trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Wachter, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology and Pneumology, University Medical Center Goettingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Gröschel, PD Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic and Policlinic for Neurology, University of Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Cardiology and Pneumology, University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic and Policlinic for Neurology, University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Nordwest-Hospital Sanderbusch</name>
      <address>
        <city>Sande</city>
        <zip>26452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, HSK, Dr. Horst-Schmidt-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, Seegers J, Wasser K, Schulte A, Jürries F, Messerschmid A, Behnke N, Gröschel S, Uphaus T, Grings A, Ibis T, Klimpe S, Wagner-Heck M, Arnold M, Protsenko E, Heuschmann PU, Conen D, Weber-Krüger M; Find-AF(randomised) Investigators and Coordinators. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF(RANDOMISED)): an open-label randomised controlled trial. Lancet Neurol. 2017 Apr;16(4):282-290. doi: 10.1016/S1474-4422(17)30002-9. Epub 2017 Feb 8. Erratum in: Lancet Neurol. 2017 Apr;16(4):261.</citation>
    <PMID>28187920</PMID>
  </reference>
  <reference>
    <citation>Weber-Krüger M, Gelbrich G, Stahrenberg R, Liman J, Kermer P, Hamann GF, Seegers J, Gröschel K, Wachter R; Find-AF(RANDOMISED) investigators. Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring--Find-AF(RANDOMISED) --rationale and design. Am Heart J. 2014 Oct;168(4):438-445.e1. doi: 10.1016/j.ahj.2014.06.018. Epub 2014 Jul 3.</citation>
    <PMID>25262252</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>ECG monitoring</keyword>
  <keyword>atrial fibrillation (/flutter)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01855035/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

